Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
CMS calls off program to cover GLP-1s April 23, 2026 Summary: CMS has indefinitely postponed its BALANCE program that would have subsidized GLP-1 obesity medications for Medicare members, a predictable outcome given the adverse selection risks and short-term cost challenges that make coverage financially untenable for health plans even at negotiated prices
A groundbreaking medication approved for chronic weight management and diabetes control
Wegovy semaglutide injection, commonly used for chronic weight management
Some of this can be attributed to changing habits that support better health and weight loss, but some shifts may be the result of the negative side-effects from the GLP-1s, including muscle loss and digestive issues
US$ 27.65
US$ 21.65
US$ 23.79
US$ 22.61
US$ 21.00
US$ 24.78
US$ 21.58
US$ 20.97
